Investor Alert

Jan. 18, 2022, 11:04 a.m. EST

Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Illumina Inc. (ILMN)

or Cancel Already have a watchlist? Log In

Jan 18, 2022 (3BL Media via COMTEX) -- SOURCE: Illumina

SAN DIEGO, January 18, 2022 /3BL Media/ -- Illumina Inc. /zigman2/quotes/203509482/composite ILMN +5.95% announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) for several programs in Boehringer Ingelheim's oncology pipeline. The partnership aims to accelerate the development of therapy selection and precision medicines for patients with advanced cancer.

The partnership spans current and future CDx programs, with plans to add CDx claims to an in vitro diagnostic test Illumina is developing that is based on the content of TruSight(TM) Oncology 500 (TSO 500). The first program will co-develop a CDx for a Boehringer Ingelheim investigational medicine.

About TruSight Oncology 500
TSO 500 is a Research Use Only comprehensive pan-cancer assay designed to identify 523 known and emerging tumor biomarkers. TSO 500 utilizes both DNA and RNA from tumor samples to identify key variants critical for cancer development and progression, such as small DNA variants, fusions, and splice variants. Based on the content of TSO 500, Illumina will be adding an in vitro diagnostic test to the TruSight Oncology product family. This comprehensive tumor profiling assay will have similar chemistry and analytics to TSO 500. To learn more about TSO 500, click here.

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter , Facebook , LinkedIn , Instagram , and YouTube .

Salli Schwartz

Dr. Karen Birmingham
EMEA: +44 7500 105665
US: 646.355.2111

Tweet me: To help improve care across the cancer journey, @illumina has invested further in therapy selection. They continue to work with their 11 pharma partners, and their newest partner @Boehringer to bring a distributed solution to the market. Learn more here: https://bit.ly/33oYcLc

KEYWORDS: illumina, NASDAQ: ILMN, Boehringer Ingelheim, TruSight Oncology 500

Female doctor consulting with a female patient.


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

US : U.S.: Nasdaq
$ 258.06
+14.49 +5.95%
Volume: 1.22M
May 27, 2022 4:00p
P/E Ratio
Dividend Yield
Market Cap
$38.26 billion
Rev. per Employee

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.